A new survey shows that most people would rather try dieting to lose weight than take the latest injectable drugs like ...

As that figure was large, weight loss drug producer Eli Lilly (NYSE: LLY) saw a nearly 2% bump in its share price in response ...

Fueled by the rise of the blockbuster GLP-1 drugs, including Ozempic and Wegovy, thinness appears to be making a comeback in ...

A trade group for large compounding pharmacies sued the FDA over its move to take Eli Lilly’s blockbuster GLP-1 drug off its ...

On October 2, 2024, the U.S. Food and Drug Administration (FDA) determined the shortage of the tirzepatide injection, a glucagon-like peptide ...

With the addition of compounded semaglutide [GLP-1], we are expanding our offering to include a clinical weight management ...

Expensive weight-loss drugs like Ozempic, Wegovy are often in short supply. Should we turn to OTC supplements that promise ...

While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.

As more Americans are prescribed glucagon-like peptide-1 receptor agonist drugs, concerns are rising about how to best manage associated adverse ...

Research highlights how GLP-1 receptor agonists may improve brain health by targeting the neurovascular unit, linking ...

Mice given semaglutide, the key ingredient in drugs like Ozempic and Wegovy, lost weight, but they also voluntarily ran less on a wheel.

GLP-1 drugs are being recommended on social media, raising questions about who can see the content and what the effects might ...